Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 5/2015

01-10-2015 | Short Communication

A1c value for diabetes diagnosis in subjects with established cardiovascular disease

Authors: A. Luzi, S. Rizza, M. Cardellini, C. Pecchioli, G. Di Cola, F. Davato, O. Porzio, A. Ippoliti, M. Copetti, M. Federici

Published in: Acta Diabetologica | Issue 5/2015

Login to get access

Excerpt

The prevalence of type 2 diabetes (DM2) is increasing at an alarming rate, and the early detection and intervention in DM2 are now considered one of the most important public health agendas. Currently, there are three different available methods for early DM2 diagnosis. …
Literature
1.
Authors/Task Force Members, Rydén L, Grant PJ et al. (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087
2.
Sun X, Du T, Huo R, Xu L (2014) Hemoglobin A1c as a marker for identifying diabetes and cardiovascular risk factors: the China Health and Nutrition Survey 2009. Acta Diabetol 51:353–360CrossRefPubMed
3.
4.
Doerr R, Hoffmann U, Otter W et al (2011) Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography: the silent diabetes study. Diabetologia 54:2923–2930CrossRefPubMed
5.
Rizza S, Copetti M, Cardellini M et al (2012) Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention. Atherosclerosis 223(2):448–453CrossRefPubMed
Metadata
Title
A1c value for diabetes diagnosis in subjects with established cardiovascular disease
Authors
A. Luzi
S. Rizza
M. Cardellini
C. Pecchioli
G. Di Cola
F. Davato
O. Porzio
A. Ippoliti
M. Copetti
M. Federici
Publication date
01-10-2015
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2015
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-015-0729-9

Other articles of this Issue 5/2015

Acta Diabetologica 5/2015 Go to the issue

Original Article

Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype

Original Article

Advanced glycation end product (AGE)-induced hepatic stellate cell activation via autophagy contributes to hepatitis C-related fibrosis

Original Article

High-sensitivity C-reactive protein, but not white blood cell count, independently predicted incident diabetes in a Japanese health screening population

Original Article

Long-term effects of baroreflex activation therapy on glucose metabolism

Review Article

Understanding type 2 diabetes: from genetics to epigenetics

Original Article

Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits